These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. How common is truly benign MS in a UK population? Tallantyre EC; Major PC; Atherton MJ; Davies WA; Joseph F; Tomassini V; Pickersgill TP; Harding KE; Willis MD; Winter M; Robertson NP J Neurol Neurosurg Psychiatry; 2019 May; 90(5):522-528. PubMed ID: 30177509 [TBL] [Abstract][Full Text] [Related]
4. Can we predict benign multiple sclerosis? Results of a 20-year long-term follow-up study. Sartori A; Abdoli M; Freedman MS J Neurol; 2017 Jun; 264(6):1068-1075. PubMed ID: 28417192 [TBL] [Abstract][Full Text] [Related]
5. Estimating typical multiple sclerosis disability progression speed from clinical observations. Brown MG; Asbridge M; Hicks V; Kirby S; Murray TJ; Andreou P; Lin D PLoS One; 2014; 9(10):e105123. PubMed ID: 25329469 [TBL] [Abstract][Full Text] [Related]
6. Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple Sclerosis. Dimisianos N; Rodi M; Kalavrizioti D; Georgiou V; Papathanasopoulos P; Mouzaki A Mult Scler Int; 2014; 2014():436764. PubMed ID: 25152817 [TBL] [Abstract][Full Text] [Related]
7. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Gajofatto A; Calabrese M; Benedetti MD; Monaco S Dis Markers; 2013; 35(6):687-99. PubMed ID: 24324285 [TBL] [Abstract][Full Text] [Related]
8. Global N-acetylaspartate concentration in benign and non-benign multiple sclerosis patients of long disease duration. Achtnichts L; Gonen O; Rigotti DJ; Babb JS; Naegelin Y; Penner IK; Bendfeldt K; Hirsch J; Amann M; Kappos L; Gass A Eur J Radiol; 2013 Dec; 82(12):e848-52. PubMed ID: 24041438 [TBL] [Abstract][Full Text] [Related]
9. Disability in multiple sclerosis: a reference for patients and clinicians. Kister I; Chamot E; Salter AR; Cutter GR; Bacon TE; Herbert J Neurology; 2013 Mar; 80(11):1018-24. PubMed ID: 23427319 [TBL] [Abstract][Full Text] [Related]
11. Two-year serial whole-brain N-acetyl-L-aspartate in patients with relapsing-remitting multiple sclerosis. Rigotti DJ; Inglese M; Kirov II; Gorynski E; Perry NN; Babb JS; Herbert J; Grossman RI; Gonen O Neurology; 2012 May; 78(18):1383-9. PubMed ID: 22517095 [TBL] [Abstract][Full Text] [Related]